DiogenX is a preclinical stage biotech company dedicated to developing innovative biologics aimed at providing new therapeutic options for diabetic patients, particularly those with type 1 diabetes (T1D). The company is focused on regenerating insulin-producing beta cells in the pancreas, with its lead candidate, DGX-01, being a first-in-class recombinant protein designed to replicate these cells. This novel approach has the potential to serve as a disease-modifying therapy for T1D, which is a chronic autoimmune condition affecting millions globally. DiogenX is currently advancing DGX-01 into IND-enabling studies, marking a significant step towards clinical development.

The leadership team at DiogenX includes experienced professionals such as Dr. Hélène Sicard, who has over 25 years of experience in biotechnology and has successfully transitioned multiple drug candidates from preclinical to early clinical stages. The company has also strengthened its team with the addition of other key personnel, enhancing its capabilities in drug development and regulatory processes. DiogenX's commitment to restoring insulin independence for patients underscores its mission to innovate in the field of diabetes treatment, leveraging its scientific expertise and strategic growth initiatives.

France

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).



DiogenX

Company Details